Literature DB >> 34994579

Body mass index as a predictor of MS activity and progression among participants in BENEFIT.

Juan Manuel Escobar1, Marianna Cortese2, Gilles Edan3, Mark S Freedman4, Hans-Peter Hartung5, Xavier Montalbán6, Rupert Sandbrink7, E-W Radü8, Frederik Barkhof9, Eva-Maria Wicklein10, Ludwig Kappos8, Alberto Ascherio11, Kassandra L Munger2.   

Abstract

BACKGROUND: There is a lack of studies on the association between obesity and conversion from a clinically isolated syndrome (CIS) to multiple sclerosis (MS).
OBJECTIVE: The aim of this study was to determine whether obesity predicts disease activity and prognosis in patients with CIS.
METHODS: Body mass index (BMI) at baseline was available for 464 patients with CIS in BENEFIT. Obesity was defined as BMI ⩾ 30 kg/m2 and normal weight as 18.5 ⩽ BMI < 25. Patients were followed up for 5 years clinically and by magnetic resonance imaging. Hazard of conversion to clinically definite (CDMS) or to 2001 McDonald criteria (MDMS) MS, annual rate of relapse, sustained progression on Expanded Disability Status Scale (EDSS), change in brain and lesion volume, and development of new brain lesions were evaluated.
RESULTS: Obese individuals were 39% more likely to convert to MDMS (95% CI: 1.02-1.91, p = 0.04) and had a 59% (95% CI: 1.01-2.31, p = 0.03) higher rate of relapse than individuals with normal weight. No associations were observed between obesity and conversion to CDMS, sustained progression on EDSS or magnetic resonance imaging (MRI) outcomes, except for a larger reduction of brain volume in obese smokers as compared to normal weight smokers (-0.82%; 95% CI: -1.51 to -0.12, p = 0.02).
CONCLUSION: Obesity was associated with faster conversion to MS (MDMS) and a higher relapse rate.

Entities:  

Keywords:  Clinical trials observational study; multiple sclerosis; obesity

Mesh:

Year:  2022        PMID: 34994579      PMCID: PMC9187580          DOI: 10.1177/13524585211061861

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   5.855


  28 in total

Review 1.  Multiple sclerosis--the plaque and its pathogenesis.

Authors:  Elliot M Frohman; Michael K Racke; Cedric S Raine
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

Review 2.  Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses.

Authors:  Lazaros Belbasis; Vanesa Bellou; Evangelos Evangelou; John P A Ioannidis; Ioanna Tzoulaki
Journal:  Lancet Neurol       Date:  2015-02-04       Impact factor: 44.182

3.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

Review 4.  The Pathogenesis of Obesity-Associated Adipose Tissue Inflammation.

Authors:  Atilla Engin
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

5.  Body size and risk of MS in two cohorts of US women.

Authors:  Kassandra L Munger; Tanuja Chitnis; Alberto Ascherio
Journal:  Neurology       Date:  2009-11-10       Impact factor: 9.910

Review 6.  The initiation and prevention of multiple sclerosis.

Authors:  Alberto Ascherio; Kassandra L Munger; Jan D Lünemann
Journal:  Nat Rev Neurol       Date:  2012-10-09       Impact factor: 42.937

7.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

Authors:  L Kappos; C H Polman; M S Freedman; G Edan; H P Hartung; D H Miller; X Montalban; F Barkhof; L Bauer; P Jakobs; C Pohl; R Sandbrink
Journal:  Neurology       Date:  2006-08-16       Impact factor: 9.910

8.  Body mass index, but not vitamin D status, is associated with brain volume change in MS.

Authors:  Ellen M Mowry; Christina J Azevedo; Charles E McCulloch; Darin T Okuda; Robin R Lincoln; Emmanuelle Waubant; Stephen L Hauser; Daniel Pelletier
Journal:  Neurology       Date:  2018-11-14       Impact factor: 11.800

9.  Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.

Authors:  Frederik Barkhof; Chris H Polman; Ernst-Wilhelm Radue; Ludwig Kappos; Mark S Freedman; Gilles Edan; Hans-Peter Hartung; David H Miller; Xavier Montalbán; Peter Poppe; Marlieke de Vos; Fatiha Lasri; Lars Bauer; Susanne Dahms; Klaus Wagner; Christoph Pohl; Rupert Sandbrink
Journal:  Arch Neurol       Date:  2007-09

10.  Association of Pre-Disease Body Mass Index With Multiple Sclerosis Prognosis.

Authors:  Ali Manouchehrinia; Anna Karin Hedström; Lars Alfredsson; Tomas Olsson; Jan Hillert; Ryan Ramanujam
Journal:  Front Neurol       Date:  2018-05-11       Impact factor: 4.003

View more
  1 in total

Review 1.  Microbial Metabolites in Multiple Sclerosis: Implications for Pathogenesis and Treatment.

Authors:  Eduardo Duarte-Silva; Sven G Meuth; Christina Alves Peixoto
Journal:  Front Neurosci       Date:  2022-04-28       Impact factor: 4.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.